1. Home
  2. ASMB vs DIAX Comparison

ASMB vs DIAX Comparison

Compare ASMB & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$27.84

Market Cap

499.8M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

DIAX

Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

HOLD

Current Price

$15.48

Market Cap

561.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
DIAX
Founded
2005
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
499.8M
561.9M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
ASMB
DIAX
Price
$27.84
$15.48
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$43.40
N/A
AVG Volume (30 Days)
109.9K
96.6K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
7.93%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,191,000.00
N/A
Revenue This Year
$33.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
31.30
N/A
52 Week Low
$7.75
$12.80
52 Week High
$39.71
$15.12

Technical Indicators

Market Signals
Indicator
ASMB
DIAX
Relative Strength Index (RSI) 37.34 54.72
Support Level $25.93 $15.23
Resistance Level $32.31 $15.67
Average True Range (ATR) 1.74 0.17
MACD -0.43 -0.02
Stochastic Oscillator 25.06 48.94

Price Performance

Historical Comparison
ASMB
DIAX

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.

Share on Social Networks: